LENZ Therapeutics Reports Q3 2026 Financial Results with $2.6M Product Sales; Announces CEO Succession and Strategic Reorganization
LENZ Therapeutics reported Q3 2026 product sales of $2.6 million with over 38,000 paid prescriptions, representing approximately 50% and 51% growth over Q2 2026 respectively. Net loss for Q3 2026 was $31.0 million or $0.99 per share compared to net loss of $16.7 million or $0.59 per share in Q3 2025. The Company announced CEO succession with Eef Schimmelpennink transitioning effective December 1, 2026 and CFO Dan Chevallard assuming the role of Interim President and CEO, along with a strategic reorganization exp...
Forward guidance
Key takeaways
Q3 2026 product sales of $2.6 million on over 38,000 paid prescriptions, up approximately 50% and 51% over Q2 2026
Q3 2026 net loss of $31.0 million or $0.99 per share compared to net loss of $16.7 million or $0.59 per share in Q3 2025
Nine months 2026 total revenue of $10.8 million including $6.0 million product sales and $4.8 million license revenue
Cash position of $197.3 million as of September 30, 2026
Telehealth channel contributed more than 50% of incremental prescriptions in Q3 2026
Strategic reorganization implemented in Q4 2026 expected to reduce 2027 operating expenses by more than 50% to approximately $70-75 million
Estimated $5 million in one-time net restructuring charges from reorganization
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow LENZ in real time
Get material earnings, filing, IR, and earnings-call alerts by email.